China Medical Systems gets SFDA approval for Phase II trial for cancer treatment
July 31st, 2008
China Medical System Holdings Ltd. said it has received approval from the Chinese State Food and Drug Administration (SFDA) to begin the Phase II clinical trial for CMS024-02 (Tyroservatide), a drug for the treatment of non-small cell lung cancer.
At 4:08 pm on February 11th, 2009 ahmed tahran said:
I put your blog to my facebook favourite sites.